عرض بسيط للتسجيلة

المؤلفAlaaeddine, Rana A.
المؤلفAlZaim, Ibrahim
المؤلفHammoud, Safaa H.
المؤلفArakji, Aya
المؤلفEid, Ali H.
المؤلفAbd-Elrahman, Khaled S.
المؤلفEl-Yazbi, Ahmed F.
تاريخ الإتاحة2023-08-29T10:21:48Z
تاريخ النشر2021
اسم المنشورClinical Science
المصدرScopus
الرقم المعياري الدولي للكتاب1435221
معرّف المصادر الموحدhttp://dx.doi.org/10.1042/CS20201445
معرّف المصادر الموحدhttp://hdl.handle.net/10576/46995
الملخصAntithrombotic drugs are widely used for primary and secondary prevention, as well as treatment of many cardiovascular disorders. Over the past few decades, major advances in the pharmacology of these agents have been made with the introduction of new drug classes as novel therapeutic options. Accumulating evidence indicates that the beneficial outcomes of some of these antithrombotic agents are not solely related to their ability to reduce thrombosis. Here, we review the evidence supporting established and potential pleiotropic effects of four novel classes of antithrombotic drugs, adenosine diphosphate (ADP) P2Y12-receptor antagonists, Glycoprotein IIb/IIIa receptor Inhibitors, and Direct Oral Anticoagulants (DOACs), which include Direct Factor Xa (FXa) and Direct Thrombin Inhibitors. Specifically, we discuss the molecular evidence supporting such pleiotropic effects in the context of cardiovascular disease (CVD) including endothelial dysfunction (ED), atherosclerosis, cardiac injury, stroke, and arrhythmia. Importantly, we highlight the role of DOACs in mitigating metabolic dysfunction-associated cardiovascular derangements. We also postulate that DOACs modulate perivascular adipose tissue inflammation and thus, may reverse cardiovascular dysfunction early in the course of the metabolic syndrome. In this regard, we argue that some antithrombotic agents can reverse the neurovascular damage in Alzheimer's and Parkinson's brain and following traumatic brain injury (TBI). Overall, we attempt to provide an up-to-date comprehensive review of the less-recognized, beneficial molecular aspects of antithrombotic therapy beyond reduced thrombus formation. We also make a solid argument for the need of further mechanistic analysis of the pleiotropic effects of antithrombotic drugs in the future.
راعي المشروعThis work was supported by the Medical Practice Plan [grant number #320148 (to A.F.E.)]; R.A.A. was supported by PhD Scholarships from the AUB-FM and the CNRS-L; I.A. was supported by a scholarship from the Mastercard Foundation.
اللغةen
الناشرPortland Press Ltd
الموضوعadipose inflammation
Antithrombotic drugs
cardiovascular disease
Metabolic dysfunction
neurodegeneration
العنوانThe pleiotropic effects of antithrombotic drugs in the metabolic-cardiovascular-neurodegenerative disease continuum: Impact beyond reduced clotting
النوعArticle Review
الصفحات1015-1051
رقم العدد8
رقم المجلد135
dc.accessType Abstract Only


الملفات في هذه التسجيلة

الملفاتالحجمالصيغةالعرض

لا توجد ملفات لها صلة بهذه التسجيلة.

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة